GALT

Galectin Therapeutics Inc

GALT, USA

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

https://galectintherapeutics.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GALT
stock
GALT

$GALT stock is down 11% today. Here's what we see in our data. Quiver Quantitative

Read more →
GALT
stock
GALT

Galectin Therapeutics (NASDAQ:GALT) Director Sells $105,273.30 in Stock MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$6

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-3.06

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

6.53 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-63.61 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 19.12% of the total shares of Galectin Therapeutics Inc

1.

Vanguard Group Inc

(3.4101%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(2.1163%)

since

2025/07/31

3.

Advisor Group Holdings, Inc.

(1.9753%)

since

2025/06/30

4.

BlackRock Inc

(1.3923%)

since

2025/06/30

5.

Jane Street Group LLC

(1.1687%)

since

2025/06/30

6.

Geode Capital Management, LLC

(1.0399%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8478%)

since

2025/07/31

8.

Sontag Advisory LLC

(0.7485%)

since

2025/06/30

9.

Geneos Wealth Management Inc

(0.6607%)

since

2025/06/30

10.

LPL Financial Corp

(0.5729%)

since

2025/06/30

11.

Commonwealth Equity Services Inc

(0.4455%)

since

2025/06/30

12.

Fidelity Extended Market Index

(0.4193%)

since

2025/07/31

13.

Morgan Stanley - Brokerage Accounts

(0.3257%)

since

2025/06/30

14.

State Street Corp

(0.3137%)

since

2025/06/30

15.

Sovran Advisors, LLC

(0.3119%)

since

2025/03/31

16.

Susquehanna International Group, LLP

(0.3016%)

since

2025/06/30

17.

Vivaldi Capital Management, LLC

(0.2692%)

since

2025/06/30

18.

UBS Group AG

(0.262%)

since

2025/06/30

19.

RETIREMENT GUYS FORMULA LLC

(0.2491%)

since

2025/06/30

20.

Millennium Management LLC

(0.2256%)

since

2025/06/30

21.

Soltis Investment Advisors, LLC

(0.2197%)

since

2025/06/30

22.

CAMBRIDGE Invest RESEARCH ADVISORS, INC.

(0.1894%)

since

2025/06/30

23.

Northern Trust Corp

(0.1885%)

since

2025/06/30

24.

iShares Micro-Cap ETF

(0.1583%)

since

2025/08/31

25.

Extended Equity Market Fund K

(0.1393%)

since

2025/06/30

26.

Fidelity Total Market Index

(0.1362%)

since

2025/07/31

27.

Fidelity Nasdaq Composite ETF

(0.1239%)

since

2025/08/29

28.

Fidelity Series Total Market Index

(0.1088%)

since

2025/07/31

29.

Fidelity Nasdaq Composite Index

(0.1062%)

since

2025/07/31

30.

Spartan Extended Market Index Pool F

(0.0955%)

since

2025/07/31

31.

NT Ext Equity Mkt Idx Fd - L

(0.0933%)

since

2025/06/30

32.

Northern Trust Extended Eq Market Idx

(0.0933%)

since

2025/06/30

33.

Horizon Kinetics Medical ETF

(0.0839%)

since

2025/08/29

34.

NT Ext Equity Mkt Idx Fd - NL

(0.0611%)

since

2025/06/30

35.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0583%)

since

2024/12/31

36.

Spartan Total Market Index Pool G

(0.0524%)

since

2025/07/31

37.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0474%)

since

2025/06/30

38.

Vanguard Balanced Index Inv

(0.042%)

since

2025/07/31

39.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0383%)

since

2025/07/31

40.

Vanguard U.S. Eq Idx £ Acc

(0.0282%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.18

Latest Release

Date

2025-09-30

EPS Actual

-0.13

EPS Estimate

-0.18

EPS Difference

0.05

Surprise Percent

27.7778%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(0.5)
Value
Overpriced(1)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.